Illumina raises $750M in senior notes to swap out pricier debt
What's the deal? Illumina has filed a free-writing prospectus supplement with the US Securities and Exchange Commission, announcing a new offering of unsecured senior notes maturing in late 2029. The notes rank equally with the genomics company's other unsecured debt and are expected to provide approximately $750 million.
Why now? Proceeds are earmarked primarily for repayment of an earlier 4.65% note due in September 2026. By retiring higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio.
The terms: The coupon has been set to place the yield near the current US Treasury benchmark. A change-of-control trigger obligates Illumina to purchase the notes at 101% of principal plus interest, while the company can redeem them early subject to a make-whole premium.
What it means: Illumina says the financing supports continued investment in next-generation sequencing platforms, data analytics and cloud-based services. The company carries MoodyDealroom has a profile for this one. Try Dealroom →'s A-3 and S&P GlobalDealroom has a profile for this one. Try Dealroom → A- credit ratings.
The signal: The raise sits in the 90th percentile by size among post-IPO debt rounds in health, based on a sample of 2,007 deals. It highlights how established genomics players are using debt to refinance while continuing to invest in growth.
Read more: AktienSensor
Image credit: joncallas
